Skip to Content
Merck
  • Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity.

Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity.

Diabetes (2014-03-22)
Mawadda Alnaeeli, Bruce M Raaka, Oksana Gavrilova, Ruifeng Teng, Tatyana Chanturiya, Constance Tom Noguchi
ABSTRACT

Obesity-induced white adipose tissue (WAT) inflammation and insulin resistance are associated with macrophage (Mф) infiltration and phenotypic shift from "anti-inflammatory" M2-like to predominantly "proinflammatory" M1-like cells. Erythropoietin (EPO), a glycoprotein hormone indispensable for erythropoiesis, has biological activities that extend to nonerythroid tissues, including antiapoptotic and anti-inflammatory effects. Using comprehensive in vivo and in vitro analyses in mice, EPO treatment inhibited WAT inflammation, normalized insulin sensitivity, and reduced glucose intolerance. We investigated EPO receptor (EPO-R) expression in WAT and characterized the role of its signaling during obesity-induced inflammation. Remarkably, and prior to any detectable changes in body weight or composition, EPO treatment reduced M1-like Mф and increased M2-like Mф in WAT, while decreasing inflammatory monocytes. These anti-inflammatory effects were found to be driven, at least in part, by direct EPO-R response in Mф via Stat3 activation, where EPO effects on M2 but not M1 Mф required interleukin-4 receptor/Stat6. Using obese ∆EpoR mice with EPO-R restricted to erythroid cells, we demonstrated an anti-inflammatory role for endogenous EPO. Collectively, our findings identify EPO-R signaling as a novel regulator of WAT inflammation, extending its nonerythroid activity to encompass effects on both Mф infiltration and subset composition in WAT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Erythropoietin human, EPO, recombinant, expressed in HEK 293 cells, suitable for cell culture